Breaking News Instant updates and real-time market news.

FEYE

FireEye

$16.98

-0.16 (-0.93%)

, PANW

Palo Alto Networks

$141.75

-1.12 (-0.78%)

21:49
09/20/17
09/20
21:49
09/20/17
21:49

SEC discloses hack of Edgar system in 2016

Securities and Exchange Commission Chairman Jay Clayton in a statement late Wednesday on cybersecurity disclosed the agency itself was the victim of a hack in 2016. Clayton explained, "Notwithstanding our efforts to protect our systems and manage cybersecurity risk, in certain cases cyber threat actors have managed to access or misuse our systems. In August 2017, the Commission learned that an incident previously detected in 2016 may have provided the basis for illicit gain through trading. Specifically, a software vulnerability in the test filing component of our EDGAR system, which was patched promptly after discovery, was exploited and resulted in access to nonpublic information. We believe the intrusion did not result in unauthorized access to personally identifiable information, jeopardize the operations of the Commission, or result in systemic risk. Our investigation of this matter is ongoing, however, and we are coordinating with appropriate authorities. As another example, our Division of Enforcement has investigated and filed cases against individuals who we allege placed fake SEC filings on our EDGAR system in an effort to profit from the resulting market movement." Publicly traded companies in the cybersecurity space include Barracuda (CUDA), Check Point (CHKP), F5 Networks (FFIV), FireEye (FEYE), Fortinet (FTNT), Imperva (IMPV), Palo Alto Networks (PANW), Proofpoint (PFPT), Qualys (QLYS) and Symantec (SYMC). Reference Link

FEYE

FireEye

$16.98

-0.16 (-0.93%)

PANW

Palo Alto Networks

$141.75

-1.12 (-0.78%)

QLYS

Qualys

$52.45

0.25 (0.48%)

CHKP

Check Point

$111.27

-1.71 (-1.51%)

PFPT

Proofpoint

$92.19

0.32 (0.35%)

FTNT

Fortinet

$38.24

-0.3 (-0.78%)

SYMC

Symantec

$33.72

-0.44 (-1.29%)

IMPV

Imperva

$44.45

-0.15 (-0.34%)

FFIV

F5 Networks

$116.83

0.07 (0.06%)

CUDA

Barracuda

$24.32

-0.15 (-0.61%)

  • 21

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 10

    Oct

  • 18

    Oct

  • 19

    Oct

FEYE FireEye
$16.98

-0.16 (-0.93%)

09/11/17
09/11/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. MasterCard (MA) upgraded to Buy from Neutral at Guggenheim. 2. FireEye (FEYE) upgraded to Overweight from Equal Weight at Stephens with analyst Jonathan Ruykhaver saying he believes consensus expectations are modeling a decline in product revenue this year, though he thinks this is too low given the refresh opportunity from appliance sales about 3 years ago. 3. Teva (TEVA) upgraded to Buy from Neutral at BTIG with analyst Timothy Chiang saying the company's appointment of Kare Schultz as its new CEO is "a positive catalyst that should help create a floor for the shares and provide a boost to near-term investor sentiment." 4. Incyte (INCY) upgraded to Outperform from Market Perform at Raymond James with analyst Reni Benjamin citing increased confidence in the probability of success of the ongoing Phase III ECHO-301, Epa plus pembrolizumab study, the commercial prospects of the Epa franchise in melanoma and at least four other tumor types, as well as the U.S. commercial opportunity for baricitinib. 5. QuickLogic (QUIK) upgraded to Buy from Neutral at Roth Capital with analyst Suji Desilva saying he believes its revenues are better positioned for upside revisions. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/11/17
SPHN
09/11/17
UPGRADE
Target $22
SPHN
Overweight
FireEye upgraded to Overweight from Equal Weight at Stephens
Stephens analyst Jonathan Ruykhaver upgraded FireEye to Overweight from Equal Weight, as he believes consensus expectations are modeling a decline in product revenue this year, though he thinks this is too low given the refresh opportunity from appliance sales about 3 years ago. Also, he likes the competitive position of the company's Helix platform, he tells investors. Ruykhaver raised his price target on FireEye shares to $22 from $16.
09/18/17
STPT
09/18/17
DOWNGRADE
STPT
Hold
FireEye downgraded to Hold from Buy at Standpoint Research
09/18/17
STPT
09/18/17
DOWNGRADE
STPT
Hold
Follow-up: FireEye downgraded to Hold on valuation at Standpoint Research
As previously reported, Standpoint Research downgraded FireEye to Hold from Buy. Analyst Ronnie Moss said shares are up over 32% since his recommendation in January and are nearing his $18 price target.
PANW Palo Alto Networks
$141.75

-1.12 (-0.78%)

09/05/17
IMPC
09/05/17
UPGRADE
Target $165
IMPC
Outperform
Palo Alto upgraded to Outperform with $165 target at Imperial Capital
Imperial Capital analyst Michael Kim upgraded Palo Alto Networks to Outperform from In-Line and raised his price target for the shares to $165 from $137. In a midday research note, the analyst highlights the company's "strong progress" on its sales force reorganization as well as lower discounting relative to last year. Kim believes consistent sales execution and improving visibility could get investors increasingly constructive on the shares.
09/05/17
IMPC
09/05/17
UPGRADE
IMPC
Outperform
Palo Alto Networks upgraded to Outperform from In-Line at Imperial Capital
09/05/17
SMTR
09/05/17
UPGRADE
SMTR
Buy
Palo Alto Networks upgraded to Buy from Hold at Summit Redstone
09/05/17
ARGS
09/05/17
UPGRADE
ARGS
Buy
Palo Alto Networks upgraded based on results at Argus
As noted earlier, Argus upgraded Palo Alto to Buy from Hold. Analyst Joseph Bonner says that the company's fiscal Q4 results indicate that it has overcome its "recent sales execution issues." He predicts that it will "be a leader in the emerging field of automated security analytics based on machine learning." Target $183.
QLYS Qualys
$52.45

0.25 (0.48%)

08/03/17
JPMS
08/03/17
UPGRADE
Target $55
JPMS
Overweight
Qualys upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Sterling Auty upgraded Qualys to Overweight and raised his price target for the shares to $55 from $40. After five straight quarters of revenue deceleration, the company's sales are set to reaccelerate in the back half of the year, Auty tells investors in a post-earnings research note. He sees a "very attractive" cash flow profile.
03/30/17
03/30/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sunoco (SUN) initiated with a Sell at Goldman. 2. CyberArk (CYBR) initiated with an Equal Weight at Morgan Stanley. 3. Humana (HUM) reinstated with an Outperform at Oppenheimer. 4. Qualys (QLYS) initiated with an Overweight at Morgan Stanley. 5. Alexion (ALXN), AveXis (AVXS), and Spark Therapeutics (ONCE) were initiated with a Buy at UBS, while Alnylam (ALNY) and BioMarin (BMRN) were initiated with a Neutral, and United Therapeutics (UTHR) was initiated with a Sell. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/06/17
SUSQ
06/06/17
INITIATION
Target $45
SUSQ
Neutral
Qualys initiated with a Neutral at Susquehanna
Susquehanna analyst Anne Meisner initiated Qualys with a Neutral and a $45 price target given strong year-to-date performance.
05/05/17
IMPC
05/05/17
NO CHANGE
Target $46
IMPC
Outperform
Qualys price target raised to $46 from $40 at Imperial Capital
Imperial Capital analyst Michael Kim raise his price target on Qualys after the company's Q1 results topped his forecast, saying he sees an upward bias to estimates as the company's new solution get adopted and its enterprise sales force expands. Kim keeps an Outperform rating on Qualys shares.
CHKP Check Point
$111.27

-1.71 (-1.51%)

08/17/17
BTIG
08/17/17
NO CHANGE
Target $118
BTIG
Buy
Check Point recent pullback a buying opportunity, says BTIG
BTIG analyst Joel Fishbein views the recent 5% post-earnings pullback in shares of Check Point Software as a buying opportunity. The company's Infinity Platform offers a potential catalyst as companies continue to consolidate vendors, Fishbein tells investors in a research note. He has a Buy rating on Check Point with a $118 price target.
07/21/17
07/21/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) was downgraded to Sell from Neutral at BTIG and to Underweight from Neutral at Atlantic Equities. 2. Wells Fargo (WFC) downgraded to Sell from Hold at Berenberg with analyst James Chappell saying the bank's competitive advantages have been eroded. 3. RH (RH) downgraded to Hold from Buy at Deutsche Bank with analyst Adam Sindler citing valuation with the stock up 36% over the past month and 15% this week alone. 4. Union Pacific (UNP) downgraded to Hold from Buy at Deutsche Bank with analyst Amit Mehrotra saying moderating volumes as well as risks to industrial production in the second half of the year and beyond will limit share upside over the medium term. 5. Check Point (CHKP) downgraded to Neutral from Overweight at Piper Jaffray with analyst Andrew Nowinski saying with the stock up 27% year-to-date, the valuation has now "reached a peak" given the decelerating billings, product/subscription and free cash flow growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/21/17
BOFA
07/21/17
NO CHANGE
Target $120
BOFA
Buy
Check Point FY17 remains intact, says BofA/Merrill
BofA/Merrill analyst Tal Liani said Check Point reported solid Q2 results but lowered Q3 guidance due to the timing of a local holiday. The analyst said it is a timing issue and any un-booked orders will fall into Q4 and FY17 remains intact. Liani rates Check Point a Buy with a $120 price target.
09/05/17
FBCO
09/05/17
INITIATION
Target $110
FBCO
Neutral
Check Point initiated with a Neutral at Credit Suisse
Credit Suisse analyst Brad Zelnick started Check Point with a Neutral rating and $110 price target. While the analyst is negative on the category as a whole, Check Point is his preferred firewall play on a relative basis.
PFPT Proofpoint
$92.19

0.32 (0.35%)

09/08/17
DBAB
09/08/17
NO CHANGE
Target $100
DBAB
Buy
Proofpoint price target raised to $100 from $95 at Deutsche Bank
Deutsche Bank analyst Karl Keirstead raised his price target for Proofpoint to $100 and keeps a Buy rating on the shares. The company at its analyst day upped its 2020 revenue guidance by $50M-$70M to $1.1B at the high end due entirely to traction in the Emerging Products segment, Keirstead tells investors in a research note. He continues to like Proofpoint's cloud model and its focus on email and adjacent areas.
09/08/17
STFL
09/08/17
NO CHANGE
Target $100
STFL
Buy
Proofpoint margin targets will prove conservative, says Stifel
After attending Proofpoint's analyst day, Stifel analyst Gur Talpaz noted that the company raised its 2020 revenue outlook to $1.025B-$1.1B from its prior target of about $1B, but made no change to its margin expectations. However, he believes the company's margin targets will ultimately prove conservative, adding that he is encouraged by traction with its emerging products. Talpaz keeps a Buy rating and $100 price target on Proofpoint shares.
09/11/17
PIPR
09/11/17
NO CHANGE
PIPR
Piper sees Equifax breach as positive for Symantec, FireEye, Proofpoint
Piper Jaffray analyst Andrew Nowinski views Equifax's (EFX) a cybersecurity breach as positive for Symantec (SYMC), FireEye (FEYE) and Proofpoint (PFPT). "Mega-breaches like Equifax not only create awareness for the security space, but typically result in an increase in spending by enterprises," Nowinski tells investors in a research note. Equifax offers a number of credit monitoring and identity theft protection services, similar to Symantec's LifeLock, the analyst points out. He believes Symantec should see a benefit to its LifeLock business. Nowinski adds FireEye's Mandiant has been reported to have been contracted to investigate the breach. The analyst's top picks remain Proofpoint and Symantec.
09/08/17
MACQ
09/08/17
NO CHANGE
MACQ
Beneficiaries of Equifax data breach at Macquarie
Macquarie analyst Sarah Hindlian said key beneficiaries of the Equifax (EFX) data breach are Proofpoint (PFPT) with its leading messaging solutions, Symantec (SYMC) which offers consumer identity theft services, and Imperva (IMPV) which offers web application security solutions.
FTNT Fortinet
$38.24

-0.3 (-0.78%)

07/24/17
KEYB
07/24/17
NO CHANGE
KEYB
Fortinet should be bought ahead of results, says KeyBanc
KeyBanc analyst Rob Owens recommends buying Fortinet ahead of its Q2 results. The analyst quotes resellers as saying that demand for the company's high throughput solutions is rising. He expects the company to benefit from demand for its new firewalls next year.
07/10/17
JPMS
07/10/17
NO CHANGE
JPMS
Barracuda results bode well for Security earnings, says JPMorgan
JPMorgan analyst Sterling Auty believes Barracuda Networks' (CUDA) Q1 results tonight set a positive tone for the June quarter earnings of Security names. Based on Barracuda's quarter, the analyst expects to see "good things" from Mimecast (MIME), Palo Alto Networks (PANW), Fortinet (FTNT), Check Point (CHKP) and Imperva (IMPV). Auty also recommends using any post-earnings weakness in shares of Barracuda as a buying opportunity. He believes Barracuda is one of the best positioned Security companies to capitalize on the shift to the cloud. The analyst keeps an Overweight rating on the name.
09/05/17
FBCO
09/05/17
INITIATION
Target $33
FBCO
Underperform
Fortinet initiated with an Underperform at Credit Suisse
Credit Suisse analyst Brad Zelnick started Fortinet with an Underperform rating and $33 price target as he remains convinced the weight of potential headwinds facing the company tilts the relative risk/reward balance negatively.
09/18/17
OPCO
09/18/17
NO CHANGE
Target $45
OPCO
Outperform
Equifax breach could become tailwind for Fortinet, says Oppenheimer
Following a meeting with Fortinet's (FTNT) management, Oppenheimer analyst Shaul Eyal believes the Equifax (EFX) breach could yield an effect akin to the late-2013 Target (TGT) breach, whereby heightened security awareness and an increase in involvement across boards and C-level executives which could convert into increased security budgets. Further, the analyst believes Fortinet is focused on better positioning itself for IT trends, and that its "strong growth" in subscription services remains in-tact and higher-end appliance traction remains a strong-point for its product segment. Eyal reiterates an Outperform rating and $45 price target on Fortinet's shares.
SYMC Symantec
$33.72

-0.44 (-1.29%)

09/06/17
MOFT
09/06/17
INITIATION
Target $33
MOFT
Neutral
Symantec initiated with a Neutral at MoffettNathanson
MoffettNathanson analyst Adam Holt initiated Symantec with a Neutral and a $33 price target citing limited earnings growth and valuation.
09/11/17
RILY
09/11/17
NO CHANGE
Target $4
RILY
Buy
Finjan one step closer to large jury award or settlement, says B. Riley
B. Riley analyst Andrew D'Silva says Finjan Holdings (FNJN) is one step closer to either collecting a large jury award or crafting an even larger global settlement and cross license after the United States Court of Appeals for the Federal Circuit heard Symantec (SYMC) unit Blue Coat's appeal. The analyst believes Blue Coat will be "left on the hook" for not only the $39.5M awarded to Finjan but also for continued infringement of additional Finjan intellectual property. He has a Buy rating on Finjan shares with a $4 price target.
IMPV Imperva
$44.45

-0.15 (-0.34%)

06/20/17
EVER
06/20/17
NO CHANGE
EVER
CyberArk, Imperva added to Small'Medium Ideas List at Evercore ISI
Evercore ISI analyst Ken Talanian added CyberArk (CYBR) and Imperva (IMPV) to the firm's Small/Medium Core Ideas List and dropped FireEye (FEYE) and Proofpoint (PFPT) from the list. The analyst says that CyberArk and Imperva are better positioned to benefit from the EU's General Data Protection Regulation, or GDPR, which seeks to strengthen the bloc's data security capabilities by forcing companies to meet certain standards by May 2018. The analyst says that CyberArk is well-positioned to be boosted by GDPR because of its focus on insider threats, while Imperva's focus on data security makes it "especially likely to benefit" from GDPR, according to the analyst.
08/28/17
PIPR
08/28/17
NO CHANGE
Target $58
PIPR
Overweight
Imperva fixed issues that impacted Q2, says Piper Jaffray
After spending time with management, Piper Jaffray analyst Andrew Nowinski says the issues that impacted Imperva's Q2 results, mostly compensation plans for various sales teams, have been resolved. The analyst adds, however, that it may take two quarters before the changes impact the financials. Imperva still has competitive advantages in a large and growing market opportunity, which should support 20% growth, Nowinski tells investors in a research note. He reiterates an Overweight rating on the shares with a $58 price target.
FFIV F5 Networks
$116.83

0.07 (0.06%)

09/12/17
NEED
09/12/17
NO CHANGE
NEED
Gigamon outlook positive, shares could reach $55-$60, says Needham
After media outlets reported that Elliott Management's private equity arm had submitted a bid to acquire Gigamon (GIMO), Needham analyst Alex Henderson believes that there are "three likely outcomes" to the situation: Gigamon will be acquired by private equity firms for $50+; Gigamon becomes a takeover target for strategic players such as F5 (FFIV), Oracle (ORCL), HP (HPE), and Juniper (JNPR);, or the company reports strong Q3 and Q4 results and the stock rallies. The analyst says that the stock could reach $55-$60 if a bidding war materializes. He reiterates a $50 price target and a Buy rating on the shares.
07/27/17
WELS
07/27/17
DOWNGRADE
Target $120
WELS
Market Perform
F5 Networks downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Jess Lubert downgraded F5 Networks to Market Perform and lowered his price target for the shares to $120 from $145 citing a deteriorating product growth outlook following the company's Q3 results. Product growth no longer seems likely to accelerate anytime soon, and may actually decline each of the next three quarters, despite the launch of multiple new products, Lubert tells investors in a post-earnings research note. Oppenheimer this morning also downgraded shares of F5.
07/27/17
OPCO
07/27/17
DOWNGRADE
OPCO
Perform
F5 Networks downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Ittai Kidron downgraded F5 Networks to Perform citing the "lackluster" June quarter results and September quarter guidance. The results suggest F5's iSeries BIG-IP product cycle isn't driving the acceleration in year-over-year revenue growth as expected, Kidron tells investors in a research note.
07/27/17
07/27/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AstraZeneca (AZN) downgraded to Market Perform from Outperform at Leerink with analyst Seamus Fernandez citing the company's "continued reliance on externalization profits and deteriorating earnings quality." 2. F5 Networks (FFIV) was downgraded to Market Perform from Outperform at Wells Fargo and to Perform from Outperform at Oppenheimer. 3. UMC (UMC) was downgraded to Underperform from Neutral at Credit Suisse and to Underperform from Market Perform at Bernstein. 4. U.S. Steel (X) and AK Steel (AKS) were downgraded to Neutral from Buy at Longbow. 5. Dean Foods (DF) downgraded to Underperform from Market Perform at Bernstein with analyst Alexia Howard saying she believes that retailers are increasingly using cheap, private label milk in order to compete with low price competitors. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CUDA Barracuda
$24.32

-0.15 (-0.61%)

07/20/17
BTIG
07/20/17
NO CHANGE
Target $30
BTIG
Buy
Barracuda set-up favorable for Q2 upside, says BTIG
BTIG analyst Joel Fishbein Jr. said he believes Barracuda Networks is set-up favorably for upside both in Q2 and for the full year with its gross margins set to improve and its Public cloud success and new products providing potential upside to renewal rates. He reiterates his Buy rating and $30 price target on Barracuda shares.
07/11/17
JPMS
07/11/17
NO CHANGE
Target $35
JPMS
Overweight
Barracuda pullback a buying opportunity, says JPMorgan
JPMorgan analyst Sterling Auty recommends using the post-earnings pullback in shares of Barracuda Networks as a buying opportunity. While bears will focus on the company's the sequential decline in Q2 revenue and earnings, investors should focus on the revenue acceleration, 20% growth in core billings and commentary around the fast growing cloud business, Auty tells investors in a research note. He keeps an Overweight rating on the shares and upped his price target for Barracuda to $35 from $33.
07/06/17
KEYB
07/06/17
NO CHANGE
KEYB
Outlook for IT security names positive, says KeyBanc
KeyBanc analyst Rob Owens expects "robust spending" on IT security in 2018, driven by the EU's GDPR requirements and sales of new firewall products, as well as the impact of recent attacks. As a result, he says that the set-up for IT security names into 2H17 is positive. He identifies Barracuda (CUDA), Fortinet (FTNT), Okta (OKTA), Palo Alto Networks (PANW), and Rapid7 (RPD) as his favorite names in the space.

TODAY'S FREE FLY STORIES

05:30
10/23/17
10/23
05:30
10/23/17
05:30
General news
FX Action: USD-JPY has remained settled under 114.00 »

FX Action: USD-JPY has…

NVS

Novartis

$85.74

-0.42 (-0.49%)

05:29
10/23/17
10/23
05:29
10/23/17
05:29
Hot Stocks
Novartis receives FDA Breakthrough Therapy Designation for Tafinlar/Mekinist »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 06

    Nov

  • 08

    Nov

  • 13

    Nov

  • 30

    Nov

  • 04

    Dec

  • 17

    May

BA

Boeing

$264.75

5.71 (2.20%)

05:25
10/23/17
10/23
05:25
10/23/17
05:25
Hot Stocks
Boeing, Mitsubishi Heavy reach agreement on cost reduction for 787 production »

Boeing and Mitsubishi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

BAC

Bank of America

$27.17

0.59 (2.22%)

05:24
10/23/17
10/23
05:24
10/23/17
05:24
Hot Stocks
Merrill Lynch fined $45.5M in Britain for not reporting derivative transactions »

Bank of America's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

ATHN

athenahealth

$126.04

9.63 (8.27%)

05:18
10/23/17
10/23
05:18
10/23/17
05:18
Upgrade
athenahealth rating change  »

athenahealth upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TATYY

Tate & Lyle

$33.23

-0.835 (-2.45%)

05:13
10/23/17
10/23
05:13
10/23/17
05:13
Upgrade
Tate & Lyle rating change  »

Tate & Lyle upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIO

Rio Tinto

$48.37

0.24 (0.50%)

05:12
10/23/17
10/23
05:12
10/23/17
05:12
Downgrade
Rio Tinto rating change  »

Rio Tinto downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MELI

MercadoLibre

$235.73

-0.27 (-0.11%)

05:02
10/23/17
10/23
05:02
10/23/17
05:02
Recommendations
MercadoLibre analyst commentary  »

MercadoLibre price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$338.10

-4.32 (-1.26%)

04:59
10/23/17
10/23
04:59
10/23/17
04:59
Initiation
Biogen initiated  »

Biogen assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

CELG

Celgene

$121.33

-14.63 (-10.76%)

04:56
10/23/17
10/23
04:56
10/23/17
04:56
Downgrade
Celgene rating change  »

Celgene assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

04:55
10/23/17
10/23
04:55
10/23/17
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

ASOMY

ASOS

$74.28

1.5 (2.06%)

04:55
10/23/17
10/23
04:55
10/23/17
04:55
Conference/Events
ASOS management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

04:55
10/23/17
10/23
04:55
10/23/17
04:55
General news
Breaking General news story  »

4-Week Bill Announcement…

04:55
10/23/17
10/23
04:55
10/23/17
04:55
General news
Breaking General news story  »

3-Month Bill Auction to…

PAY

Verifone

$20.06

0.06 (0.30%)

04:55
10/23/17
10/23
04:55
10/23/17
04:55
Conference/Events
Verifone management to meet with Jefferies »

Meeting to be held in Las…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 14

    Dec

PLUG

Plug Power

$2.70

0.17 (6.72%)

04:55
10/23/17
10/23
04:55
10/23/17
04:55
Conference/Events
Plug Power to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 16

    Nov

DDAIF

Daimler AG

$80.57

-1.11 (-1.36%)

04:55
10/23/17
10/23
04:55
10/23/17
04:55
Conference/Events
Daimler AG management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

04:55
10/23/17
10/23
04:55
10/23/17
04:55
General news
Chicago Fed National Activity Index Level to be reported at 08:30 »

September Chicago Fed…

IVC

Invacare

$14.60

0.05 (0.34%)

04:55
10/23/17
10/23
04:55
10/23/17
04:55
Conference/Events
Invacare management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

ALXN

Alexion

$139.02

-1.44 (-1.03%)

04:54
10/23/17
10/23
04:54
10/23/17
04:54
Initiation
Alexion initiated  »

Alexion assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 26

    Oct

  • 06

    Nov

BIVV

Bioverativ

$60.22

0.49 (0.82%)

04:52
10/23/17
10/23
04:52
10/23/17
04:52
Initiation
Bioverativ initiated  »

Bioverativ assumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 06

    Nov

TSRO

Tesaro

$116.40

0.89 (0.77%)

04:50
10/23/17
10/23
04:50
10/23/17
04:50
Downgrade
Tesaro rating change  »

Tesaro assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 06

    Nov

  • 08

    Nov

AMAG

Amag Pharmaceuticals

$15.60

-0.45 (-2.80%)

04:48
10/23/17
10/23
04:48
10/23/17
04:48
Initiation
Amag Pharmaceuticals initiated  »

Amag Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

  • 02

    Feb

  • 14

    Feb

04:15
10/23/17
10/23
04:15
10/23/17
04:15
General news
FX Action: USD-CAD has remained underpinned »

FX Action: USD-CAD has…

03:05
10/23/17
10/23
03:05
10/23/17
03:05
General news
FX Update: The dollar has traded mixed »

FX Update: The dollar has…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.